IL258496A - Antibodies with improved stability for internal digestion - Google Patents

Antibodies with improved stability for internal digestion

Info

Publication number
IL258496A
IL258496A IL258496A IL25849618A IL258496A IL 258496 A IL258496 A IL 258496A IL 258496 A IL258496 A IL 258496A IL 25849618 A IL25849618 A IL 25849618A IL 258496 A IL258496 A IL 258496A
Authority
IL
Israel
Prior art keywords
antibodies
improved stability
intestinal digestion
intestinal
digestion
Prior art date
Application number
IL258496A
Other languages
English (en)
Hebrew (he)
Original Assignee
Circle33 Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circle33 Llc filed Critical Circle33 Llc
Publication of IL258496A publication Critical patent/IL258496A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL258496A 2015-10-05 2018-04-04 Antibodies with improved stability for internal digestion IL258496A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562237270P 2015-10-05 2015-10-05
PCT/US2016/054304 WO2017062253A2 (en) 2015-10-05 2016-09-29 Antibodies with improved stability to intestinal digestion

Publications (1)

Publication Number Publication Date
IL258496A true IL258496A (en) 2018-05-31

Family

ID=58488349

Family Applications (1)

Application Number Title Priority Date Filing Date
IL258496A IL258496A (en) 2015-10-05 2018-04-04 Antibodies with improved stability for internal digestion

Country Status (8)

Country Link
US (2) US11891440B2 (OSRAM)
EP (1) EP3359190A4 (OSRAM)
JP (2) JP7235287B2 (OSRAM)
AU (2) AU2016335912B2 (OSRAM)
BR (1) BR112018006953A2 (OSRAM)
CA (1) CA3039177A1 (OSRAM)
IL (1) IL258496A (OSRAM)
WO (1) WO2017062253A2 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790533B (zh) * 2016-08-15 2023-04-04 国立大学法人北海道大学 抗pd-l1抗体
WO2020123798A1 (en) * 2018-12-12 2020-06-18 President And Fellows Of Harvard College Bovine versions of fcmbl for the detection and treatment of bovine microbial infections
WO2022109313A1 (en) * 2020-11-20 2022-05-27 Zoetis Services Llc Bovine antibody variants
WO2025057225A1 (en) * 2023-09-14 2025-03-20 Invitrogen Bioservices India Private Limited Engineered antibodies and uses thereof
CN120209146A (zh) * 2025-03-31 2025-06-27 上海百英生物科技股份有限公司 一种包含非天然氨基酸修饰的Claudin 6抗体及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP2244735A4 (en) * 2007-10-02 2011-02-23 Avaxia Biologics Inc ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE
US8647626B2 (en) * 2007-10-02 2014-02-11 Avaxia Biologics, Incorporated Compositions comprising TNF-specific antibodies for oral delivery
EA201290241A1 (ru) * 2009-10-29 2013-02-28 Янссен Байотек Инк. Изменение гликозилирования антител
AR084210A1 (es) * 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
RU2013129203A (ru) * 2010-12-27 2015-02-10 Джапан Хелт Сайенсес Фаундейшн Моноклональное антитело, распознающее белок l2 папилломавируса человека (впч), и способ определения титра впч-нейтрализующего антитела, использующий такое антитело
EP2739650A4 (en) * 2011-08-01 2015-04-01 Avaxia Biologics Inc SPECIFIC BOVINE POLYCLONAL ANTIBODY OF HUMAN TNF
CN115850489A (zh) * 2016-08-15 2023-03-28 国立大学法人北海道大学 抗pd-1抗体

Also Published As

Publication number Publication date
WO2017062253A3 (en) 2017-05-11
WO2017062253A2 (en) 2017-04-13
BR112018006953A2 (pt) 2018-10-23
CA3039177A1 (en) 2017-04-13
AU2023216791A1 (en) 2023-09-07
JP2018537117A (ja) 2018-12-20
US20220073602A1 (en) 2022-03-10
EP3359190A4 (en) 2020-05-06
JP7235287B2 (ja) 2023-03-08
US11891440B2 (en) 2024-02-06
AU2016335912B2 (en) 2023-08-31
JP2022185053A (ja) 2022-12-13
US20240067715A1 (en) 2024-02-29
AU2016335912A1 (en) 2018-05-24
EP3359190A2 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
IL285287A (en) Antibodies to tigit
IL286807A (en) Antibodies to icos
IL261188A (en) Antibodies against tigit
GB2570593B (en) Methods relating to intestinal organ-on-a-chip
IL256499A (en) Antibodies to CD40
IL258496A (en) Antibodies with improved stability for internal digestion
IL248145A0 (en) ang2 antibodies
GB201609742D0 (en) Improvements relating to antibodies
ZA201802390B (en) Improved fermenter
GB201414046D0 (en) Anaerobic digestion
GB2538045B (en) Improvements to letter-plates
GB2522473B (en) Improvements to windposts
GB201418521D0 (en) Improvements to dart flights
HK1259629A1 (en) Antibodies with improved stability to intestinal digestion
GB201423383D0 (en) Improvements to darts
GB2520781B (en) Improvements to hydro-turbines
GB201521028D0 (en) Improvements to Li-fi
GB201407480D0 (en) Anaerobic digestion
GB201513916D0 (en) Improvements to underwear
GB201414608D0 (en) Improvements to structure
HK1244290A1 (en) Antibodies to tigit
GB201507228D0 (en) Antibodies to IL-24
GB201517418D0 (en) Improvement to healthcare vessels
GB201405489D0 (en) Able to go